Trial results 12 March 2025 No lost causes at Xilio and Lyell The companies press on with vilastobart and IMPT-314... up to a point. Read more
Trial results 26 June 2024 Investors don't buy Lyell's solid tumour Car-T success The ROR1 data are sketchy, and lung toxicity clouds prospects. Read more